These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 9024260

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [Abstract] [Full Text] [Related]

  • 8. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC, Hartman ML, Pezzoli SS, Thorner MO.
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
    Van den Berghe G, Wouters P, Bowers CY, de Zegher F, Bouillon R, Veldhuis JD.
    Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
    [Abstract] [Full Text] [Related]

  • 14. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R.
    Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
    [Abstract] [Full Text] [Related]

  • 15. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A, South S, Liem AY, Clemmons D, Thorner MO, Weltman A, Veldhuis JD.
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [Abstract] [Full Text] [Related]

  • 16. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
    Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
    [Abstract] [Full Text] [Related]

  • 17. Growth hormone secretagogues in critical illness.
    Van den Berghe G.
    Horm Res; 1999 Apr; 51 Suppl 3():21-8. PubMed ID: 10592440
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY, Granda-Ayala R.
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [Abstract] [Full Text] [Related]

  • 19. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [Abstract] [Full Text] [Related]

  • 20. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL.
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.